Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-12-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司人粪便DNA甲基化检测产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the registration certificate obtained by a wholly-owned subsidiary for a medical device product. It includes product details, market context, and impact on the company. There are no financial statements, no mention of annual or quarterly reports, no voting results, no management changes, no earnings data, and no regulatory certifications or legal proceedings. The document is an official announcement about a product registration approval, which fits best under general regulatory announcements that do not fit other specific categories. The document length is short (1196 characters), and it is not a report or presentation but an announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-12-18 Chinese
关于召开2023年第四次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2023 fourth extraordinary general meeting of shareholders for Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration details, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but an announcement and notice related to a shareholders' meeting. It does not contain voting results or executive changes but is a notice to shareholders about the meeting and how to participate. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-12-15 Chinese
独立董事关于第三届董事会第二十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific board meeting matters related to the adjustment of the 2022 restricted stock incentive plan grant price and the granting of reserved restricted stock to incentive recipients. It references compliance with regulatory guidelines and company articles, and it is focused on governance and board decisions about stock incentive plans. The document is not a full financial report, earnings release, or regulatory filing but rather a board/management related announcement about governance and incentive plan decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or voting result announcement either.
2023-12-01 Chinese
上海信公轶禾企业管理咨询有限公司关于深圳华大基因股份有限公司2022年限制性股票激励计划预留授予相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2022 Restricted Stock Incentive Plan of Shenzhen BGI Genomics Co., Ltd. It details the reserved grant of restricted stock, approval procedures, grant conditions, and the advisor's verification opinions. The content focuses on stock incentive plan matters, approvals, and compliance with relevant laws and regulations. It is not a general annual or quarterly financial report, nor an earnings release or management discussion. It is a specialized advisory report on a stock incentive plan, which fits best under the category of Capital/Financing Update (CAP) because it relates to equity incentive plans and share grants, which affect the company's capital structure and financing arrangements. The document length (7065 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-12-01 Chinese
董事会提名委员会实施细则（2023年12月）
Governance Information Classification · 100% confidence The document is titled '深圳华大基因股份有限公司 董事会提名委员会实施细则' which translates to 'Implementation Rules of the Board Nomination Committee of Shenzhen BGI Co., Ltd.' It details the structure, responsibilities, composition, and procedures of the Board Nomination Committee. It is a governance-related document focusing on internal rules and board committee operations. There is no financial data, no mention of financial results, no voting results, no legal proceedings, no capital changes, or other categories. It is not a report or announcement of a report but a governance practice document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2723 characters, which is sufficient for a detailed governance document but not a brief announcement or certification.
2023-12-01 Chinese
关于召开2023年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 fourth extraordinary general meeting of shareholders for Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items, registration details, and attachments such as proxy forms and shareholder registration forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2023-12-01 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.